{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 349
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 349
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:vintesomeran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:zeldesmeran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:davesomeran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID